Decoding FDA’s new flexible CMC requirements for cell and gene therapies

On January 11, 2026, the FDA announced information about the agency’s flexible approach to overseeing chemistry, manufacturing and control (CMC) requirements for cell and gene therapies (CGTs).1  

While highlighting the agency’s initiatives to facilitate the development of CGTs, the FDA announcement does require some clarifications and context for CGTs sponsors to understand how to implement the flexibilities into their development programs.  

Here we discuss some of the critical points covered in the announcement and provide our insights:

Return to Insights Center

Back

Access exclusive insights

Harness the power of clinical development with exclusive insights from our experts at Parexel

Would you like to hear from us in the future?

Stay connected with Parexel!

Accept

Decline